PARADISE-MI 2021 (Entresto in post AMI with LV dysfunction)

Patients with acute myocardial infarction (MI) received either sacubitril/valsartan or ramipril in this randomized trial, which generated a lot of debate at the American College of Cardiology (ACC.21) about whether the trial was negative (the p-value for the primary endpoint was not statistically significant) or positive (the p-value for the secondary endpoint was statistically significant) (examination of recurrent and not just first heart failure [HF] events was significant). 


Criteria for inclusion are as follows:

  • Acute myocardial infarction is the presenting symptom.
  • Left ventricular ejection fraction (LVEF) of less than 40% with or without pulmonary congestion. 


Additionally, one of the following conditions must be met: 

  1. age less than 70 years, 
  2. atrial fibrillation, 
  3. estimated glomerular filtration rate (eGFR) less than 60, 
  4. diabetes mellitus, 
  5. prior MI, 
  6. LVEF less than 30%, 
  7. Killip class III, 
  8. ST-segment elevation MI (STEMI) without reperfusion



Criteria for exclusion include:


  • Heart failure (HF) in the past; 
  • clinical instability
  • eGFR 30 mL/min


The main outcome of cardiovascular (CV) mortality, first heart failure hospitalization, or outpatient heart failure was 11.9 percent against 13.2 percent (p = 0.17), respectively, for sacubitril/valsartan and ramipril.


CV mortality rates were 5.9 percent compared to 6.7 percent (p = 0.20).

Hospitalization for heart failure (6 percent vs. 6.9 percent, p = 0.17)


Among the secondary outcomes compared between sacubitril/valsartan and ramipril were:


CV death/MI/stroke: 11.1 percent vs. 12.3 percent (p = 0.18) in the general population.

Mortality from any cause was 7.5 percent compared to 8.5 percent (p = 0.16).

Total heart failure hospitalization, outpatient heart failure episodes, and CV mortality were 8.4 versus 10.1 per 100 patient-years (p = 0.02), respectively.

Hypotension was seen in 28.4 percent versus 22.0 percent (p 0.05).


Regardless of how you interpret the results, this long-awaited trial revealed crucial insights into how sacubitril/valsartan fits into clinical practice and definitely sparked substantial interest among the general public.


Find published trial in Euro Heart failure

Comments

Post a Comment

Popular posts from this blog

MASTER DAPT Trial 2021

 In terms of net adverse clinical events, the MASTER DAPT trial found that shortened antiplatelet medication was not inferior to regular antiplatelet therapy. Description: The trial's purpose was to compare shortened antiplatelet therapy to standard antiplatelet therapy in patients who had percutaneous coronary intervention (PCI) using a biodegradable-polymer sirolimus-eluting stent. Design of the Study:  Participants with symptomatic coronary artery disease who had PCI during the previous 30-44 days were randomly assigned to one of two groups: shortened therapy (n = 2,295) or standard therapy (n = 2,284). Among people who do not require oral anticoagulation: Participants in the abbreviated therapy group promptly discontinued dual antiplatelet therapy (DAPT) and continued single antiplatelet therapy. Participants in the conventional therapy group received DAPT for 5 months before switching to mono antiplatelet medication. Those with an indication for oral anticoagulation inclu...
Read more

EMPEROR-Preserved 2021 (Empagliflozin in HFpEF)

 Empagliflozin is better than placebo in improving HF outcomes among patients with symptomatic stable HFpEF on good baseline GDMT, regardless of diabetes status, according to the EMPEROR-Preserved study. The trial's purpose was to see if empagliflozin was safe and effective in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), regardless of diabetes. Design of the Study: Patients were randomly assigned to either empagliflozin 10 mg (n = 2,997) or a placebo (n = 2,991) in a 1:1 ratio. Geographic location, diabetes status, estimated glomerular filtration rate (eGFR), and left ventricular ejection fraction were all used to stratify the experiment (LVEF: more or less than 50 percent ). All of the patients were being treated for heart failure. 11,583 people were screened in total. The total number of students enrolled is 5,988. Follow-up period: 26.2 months (median) The average patient is 72 years old. 45 percent of the population is female. The major outc...
Read more

CRAVE Trial 2021 (Coffee Intake)

 The CRAVE trial found that coffee drinking increased PVCs and decreased sleep but decreased atrial arrhythmias and boosted physical activity. "These findings add to the emerging evidence that those with supraventricular tachycardia or atrial fibrillation should not avoid coffee," researchers said.  The research, conducted by Gregory M. Marcus, MD, MA, FACC, included 100 non-Hispanic White people with a median age of 38. Each participant wore an ECG monitor, a diabetes monitor, and a Fitbit. Researchers utilized a smartphone app to collect geolocation data and genotyped participants' DNA for coffee metabolism-related SNPs. Participants were randomly assigned to drink or avoid coffee for 14 days, with daily SMS reminders.  Overall, coffee intake was related with a 54% increase in PVCs, 36 minutes less sleep per night, and 1,058 more Fitbit-based steps per day. Each extra cup of coffee was linked to 3% more daily premature atrial contractions and 18 minutes less sleep. No s...
Read more